FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3132903079> ?p ?o ?g. }

• W3132903079 endingPage "1003" @default.
• W3132903079 startingPage "993" @default.
• W3132903079 abstract "Trials done in infants with low birthweight in west Africa suggest that BCG vaccination reduces all-cause mortality in the neonatal period, probably because of heterologous protection against non-tuberculous infections. This study investigated whether BCG alters all-cause infectious disease morbidity in healthy infants in a different high-mortality setting, and explored whether the changes are mediated via trained innate immunity.This was an investigator-blind, randomised, controlled trial done at one hospital in Entebbe, Uganda. Infants who were born unwell (ie, those who were not well enough to be discharged directly home from the labour ward because they required medical intervention), with major congenital malformations, to mothers with HIV, into families with known or suspected tuberculosis, or for whom cord blood samples could not be taken, were excluded from the study. Any other infant well enough to be discharged directly from the labour ward was eligible for inclusion, with no limitation on gestational age or birthweight. Participants were recruited at birth and randomly assigned (1:1) to receive standard dose BCG 1331 (BCG-Danish) on the day of birth or at age 6 weeks (computer-generated randomisation, block sizes of 24, stratified by sex). Investigators and clinicians were masked to group assignment; parents were not masked. Participants were clinically followed up to age 10 weeks and contributed blood samples to one of three immunological substudies. The primary clinical outcome was physician-diagnosed non-tuberculous infectious disease incidence. Primary immunological outcomes were histone trimethylation at the promoter region of TNF, IL6, and IL1B; ex-vivo production of TNF, IL-6, IL-1β, IL-10, and IFNγ after heterologous stimulation; and transferrin saturation and hepcidin levels. All outcomes were analysed in the modified intention-to-treat population of all randomly assigned participants except those whose for whom consent was withdrawn. This trial is registered with the International Standard Randomised Controlled Trial Number registry (#59683017).Between Sept 25, 2014, and July 31, 2015, 560 participants were enrolled and randomly assigned to receive BCG at birth (n=280) or age 6 weeks (n=280). 12 participants assigned to receive BCG at birth and 11 participants assigned to receive BCG at age 6 weeks were withdrawn from the study by their parents shortly after randomisation and were not included in analyses. During the first 6 weeks of life before the infants in the delayed vaccination group received BCG vaccination, physician-diagnosed non-tuberculous infectious disease incidence was lower in infants in the BCG at birth group than in the delayed group (98 presentations in the BCG at birth group vs 129 in the delayed BCG group; hazard ratio [HR] 0·71 [95% CI 0·53-0·95], p=0·023). After BCG in the delayed group (ie, during the age 6-10 weeks follow-up), there was no significant difference in non-tuberculous infectious disease incidence between the groups (88 presentations vs 76 presentations; HR 1·10 [0·87-1·40], p=0·62). BCG at birth inhibited the increase in histone trimethylation at the TNF promoter in peripheral blood mononuclear cells occurring in the first 6 weeks of life. H3K4me3 geometric mean fold-increases were 3·1 times lower at the TNF promoter (p=0·018), 2·5 times lower at the IL6 promoter (p=0·20), and 3·1 times lower at the IL1B promoter (p=0·082) and H3K9me3 geometric mean fold-increases were 8·9 times lower at the TNF promoter (p=0·0046), 1·2 times lower at the IL6 promoter (p=0·75), and 4·6 times lower at the IL1B promoter (p=0·068), in BCG-vaccinated (BCG at birth group) versus BCG-naive (delayed BCG group) infants. No clear effect of BCG on ex-vivo production of TNF, IL-6, IL-1β, IL-10, and IFNγ after heterologous stimulation, or transferrin saturation and hepcidin concentration, was detected (geometric mean ratios between 0·68 and 1·68; p≥0·038 for all comparisons).BCG vaccination protects against non-tuberculous infectious disease during the neonatal period, in addition to having tuberculosis-specific effects. Prioritisation of BCG on the first day of life in high-mortality settings might have significant public-health benefits through reductions in all-cause infectious morbidity and mortality.Wellcome Trust.For the Luganda and Swahili translations of the abstract see Supplementary Materials section." @default.
• W3132903079 created "2021-03-01" @default.
• W3132903079 creator A5006858820 @default.
• W3132903079 creator A5009112001 @default.
• W3132903079 creator A5010382696 @default.
• W3132903079 creator A5011575962 @default.
• W3132903079 creator A5012672031 @default.
• W3132903079 creator A5016082976 @default.
• W3132903079 creator A5018347913 @default.
• W3132903079 creator A5023774687 @default.
• W3132903079 creator A5024359716 @default.
• W3132903079 creator A5027212627 @default.
• W3132903079 creator A5027496223 @default.
• W3132903079 creator A5027955775 @default.
• W3132903079 creator A5033426327 @default.
• W3132903079 creator A5036450200 @default.
• W3132903079 creator A5036541256 @default.
• W3132903079 creator A5048374563 @default.
• W3132903079 creator A5049793514 @default.
• W3132903079 creator A5051333438 @default.
• W3132903079 creator A5056827656 @default.
• W3132903079 creator A5058595159 @default.
• W3132903079 creator A5059544767 @default.
• W3132903079 creator A5066547819 @default.
• W3132903079 creator A5069763813 @default.
• W3132903079 creator A5070431516 @default.
• W3132903079 creator A5071583993 @default.
• W3132903079 creator A5071831898 @default.
• W3132903079 creator A5081026738 @default.
• W3132903079 creator A5084051595 @default.
• W3132903079 creator A5084518206 @default.
• W3132903079 creator A5086397490 @default.
• W3132903079 creator A5087360873 @default.
• W3132903079 creator A5089522455 @default.
• W3132903079 date "2021-07-01" @default.
• W3132903079 modified "2023-10-01" @default.
• W3132903079 title "BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial" @default.
• W3132903079 cites W1526544645 @default.
• W3132903079 cites W1588693256 @default.
• W3132903079 cites W1969974932 @default.
• W3132903079 cites W2003616952 @default.
• W3132903079 cites W2031164321 @default.
• W3132903079 cites W2033860240 @default.
• W3132903079 cites W2059403792 @default.
• W3132903079 cites W2103753861 @default.
• W3132903079 cites W2112439253 @default.
• W3132903079 cites W2141577125 @default.
• W3132903079 cites W2149605803 @default.
• W3132903079 cites W2150402710 @default.
• W3132903079 cites W2160198221 @default.
• W3132903079 cites W2485574142 @default.
• W3132903079 cites W2520003227 @default.
• W3132903079 cites W2529875271 @default.
• W3132903079 cites W2530956777 @default.
• W3132903079 cites W2549697535 @default.
• W3132903079 cites W2612737843 @default.
• W3132903079 cites W2745104623 @default.
• W3132903079 cites W2773615119 @default.
• W3132903079 cites W2791997229 @default.
• W3132903079 cites W2793717126 @default.
• W3132903079 cites W2893884783 @default.
• W3132903079 cites W2943762716 @default.
• W3132903079 cites W2969639077 @default.
• W3132903079 cites W2983763582 @default.
• W3132903079 cites W2988475092 @default.
• W3132903079 cites W3023662906 @default.
• W3132903079 cites W4244910061 @default.
• W3132903079 cites W2141475834 @default.
• W3132903079 doi "https://doi.org/10.1016/s1473-3099(20)30653-8" @default.
• W3132903079 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8222005" @default.
• W3132903079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33609457" @default.
• W3132903079 hasPublicationYear "2021" @default.
• W3132903079 type Work @default.
• W3132903079 sameAs 3132903079 @default.
• W3132903079 citedByCount "81" @default.
• W3132903079 countsByYear W31329030792021 @default.
• W3132903079 countsByYear W31329030792022 @default.
• W3132903079 countsByYear W31329030792023 @default.
• W3132903079 crossrefType "journal-article" @default.
• W3132903079 hasAuthorship W3132903079A5006858820 @default.
• W3132903079 hasAuthorship W3132903079A5009112001 @default.
• W3132903079 hasAuthorship W3132903079A5010382696 @default.
• W3132903079 hasAuthorship W3132903079A5011575962 @default.
• W3132903079 hasAuthorship W3132903079A5012672031 @default.
• W3132903079 hasAuthorship W3132903079A5016082976 @default.
• W3132903079 hasAuthorship W3132903079A5018347913 @default.
• W3132903079 hasAuthorship W3132903079A5023774687 @default.
• W3132903079 hasAuthorship W3132903079A5024359716 @default.
• W3132903079 hasAuthorship W3132903079A5027212627 @default.
• W3132903079 hasAuthorship W3132903079A5027496223 @default.
• W3132903079 hasAuthorship W3132903079A5027955775 @default.
• W3132903079 hasAuthorship W3132903079A5033426327 @default.
• W3132903079 hasAuthorship W3132903079A5036450200 @default.
• W3132903079 hasAuthorship W3132903079A5036541256 @default.
• W3132903079 hasAuthorship W3132903079A5048374563 @default.
• W3132903079 hasAuthorship W3132903079A5049793514 @default.
• W3132903079 hasAuthorship W3132903079A5051333438 @default.
• W3132903079 hasAuthorship W3132903079A5056827656 @default.

• next